Clinical Trials Logo

PCSK9 clinical trials

View clinical trials related to PCSK9.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03139630 Completed - Dyslipidemias Clinical Trials

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients

COPANA
Start date: March 2016
Phase:
Study type: Observational

Evaluation of the impact of initiation of protease inhibitor/ritonavir on PCSK9 levels in HIV-infected antiretroviral-naïve patients from the ANRS C09 COPANA cohort.

NCT ID: NCT03043365 Completed - Proteomics Clinical Trials

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

Start date: June 15, 2017
Phase: Phase 2
Study type: Interventional

Background: Fish oils are known to be beneficial to health and believed to be cardio-protective. Omega-3 fatty acid is the most known fish oil available in the market. LCMUFA (long-chain monounsaturated fatty acids) is also a fish oil but it is derived from fish that consumes a diet rich in omega-11 fatty acid. Researchers want to study omega-11 fatty acid enriched fish oil and understand its effect on cardiovascular health. Objective: To understand the effects of LCMUFA from fish oil on cardiovascular health. Eligibility: Healthy volunteers ages 18 and older with no history of cardiovascular disease Design: Participants will be screened with: - Medical history - Physical exam - Fasting blood and urine tests - Optional stool sample - Questions about their diet, exercise, and the types of medicines and dietary supplements they take - 7-day food diary - Cardio-Ankle Vascular Index (CAVI): Blood pressure is taken in the arms and legs. The heart is monitored. - After the screening visit, participants will take 4 gel capsules, 3 times a day after meals, for 8-10 weeks. - Electrocardiogram (EKG) Participants will have 3 additional visits. All include repeats of the screening tests. Visit 2 is 8 weeks after the screening visit. Participants will stop taking the capsules for 8 weeks after this visit. Visit 3 is at least 16 weeks after starting the supplement. Participants will take 4 capsules, 3 times a day after meals, for 8 weeks after this visit. Visit 4 is 8 weeks after starting the second supplement.

NCT ID: NCT02514070 Completed - Proteomics Clinical Trials

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Start date: October 30, 2015
Phase: Phase 2
Study type: Interventional

Background: - Metabolism is what the body does to turn food into energy. Omega-3 fatty acids are substances found in foods such as cold-water fish and shellfish that are essential for good health. Researchers want to see the effect of two fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on metabolism. They may be beneficial to cardiovascular health. Objective: - To understand the effects of EPA and DHA on metabolism. Eligibility: - Healthy people ages 18 years or above with plasma triglyceride (a type of fat in the blood) levels of 100 mg/dL or higher Design: - The study will last 20 to 24 weeks. - Participants will have 4 visits to the NIH Clinical Center. These will include: - Medical history - Physical Fasting blood and urine tests - CAVI tests: blood pressure is taken in the arms and legs, and the heart is monitored. - Participants will take an EPA/DHA dietary supplement. They will take 4 gel capsules, 3 times a day, for 6 or 7 weeks. Then they will not take the capsules for 8 to 10 weeks (a wash-out period). They will then take the capsules again for 6 or 7 weeks. - Participants will keep a food journal.